StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

Research analysts at StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Friday.

Senseonics Price Performance

Shares of Senseonics stock opened at $0.28 on Friday. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 2.47. Senseonics has a 52-week low of $0.28 and a 52-week high of $0.75. The stock has a market capitalization of $166.83 million, a price-to-earnings ratio of -2.17 and a beta of 0.79. The company’s 50 day moving average price is $0.35 and its 200-day moving average price is $0.40.

Institutional Trading of Senseonics

Large investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its position in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares during the period. State Board of Administration of Florida Retirement System purchased a new position in Senseonics during the first quarter valued at $91,000. Virtu Financial LLC purchased a new position in Senseonics during the first quarter valued at $162,000. GSA Capital Partners LLP purchased a new position in Senseonics during the third quarter valued at $117,000. Finally, Price T Rowe Associates Inc. MD lifted its position in Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.